| Document |
Document Title |
|
WO/2024/146614A1 |
A human papillomavirus type 51 L1 protein mutant, a method for reducing the degradation of a recombinant human papillomavirus type 51 L1 protein using same and the use thereof. The mutation of R at position 422 of the amino acid sequence...
|
|
WO/2024/148223A1 |
Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune thera...
|
|
WO/2024/148241A1 |
Provided are antibodies and antigen binding fragments thereof that bind to interleukin- 18 binding protein (IL-18BP) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the trea...
|
|
WO/2024/147344A1 |
Provided is a means which is capable of quickly and inexpensively quantifying a human insulin amount which is secreted from a human cell.　This method for quantifying insulin secretion capacity in human cells is characterized in that: a...
|
|
WO/2024/148235A1 |
Genetically engineered cells (e.g., HSPCs), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that tar...
|
|
WO/2024/147126A1 |
Provided herein are systems, devices, kits and methods for automatic purification and concentration of immunoglobulins from a biological sample. In particular, the system and methods disclosed herein facilitate the purification and conce...
|
|
WO/2024/147556A1 |
The present invention relates to a composition for an anticancer vaccine, the composition comprising, as an active ingredient, a K-ras mutant multiple epitope polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. Using the c...
|
|
WO/2024/146613A1 |
A human papillomavirus (HPV) 56-type L1 protein mutant, a method for reducing the degradation of a recombinant HPV 56-type L1 protein, and an application. The modification of mutating the R at position 420 of an amino acid sequence of HP...
|
|
WO/2024/139780A1 |
Provided are a T cell receptor targeting cytomegalovirus (CMV) pp65, and a T cell expressing the T cell receptor and a use thereof. Specifically provided is an HLA-A*1101-restricted specific T cell targeting a CMV-pp65 antigen epitope. T...
|
|
WO/2024/145006A1 |
The present disclosure relates to fusion proteins, e g., insulin-Fc fusion proteins, compositions thereof, and their use to treat cancer cells and cancer tumors in subjects in need thereof. The fusion protein exhibits an anti -tumor effe...
|
|
WO/2024/140538A1 |
Provided are systems for strand-specific editing of DNA, including mitochondrial DNA in humans. The systems provided herein comprise a single strand nickase and a deaminase each, or together, associated with a double-stranded DNA binding...
|
|
WO/2024/144336A1 |
The present invention relates to a novel bispecific fusion protein and a use thereof and, more specifically, to a bispecific fusion protein, which comprises: I) a first fusion protein sequentially comprising a) a heavy chain variable reg...
|
|
WO/2024/138833A1 |
A modified recombinant blood coagulation factor VIII and the use thereof. The B domain of the recombinant blood coagulation factor VIII comprises an SQ sequence, one or more specific vWF-binding site sequences being inserted into the SQ ...
|
|
WO/2024/145279A1 |
The disclosure relates to genetically modified microorganisms for the improvement of phenotypes of plants, for example nitrogen availability for non-leguminous plants. Included are novel strains of the microorganisms, microbial consortia...
|
|
WO/2024/144239A1 |
The present application provides a microorganism having enhanced activity of anion symporter, a composition for producing a pantothenic acid and/or pantoic acid comprising the microorganism, and a method for producing a pantothenic acid ...
|
|
WO/2024/144382A1 |
The present application relates to: a novel BBD29_RS14450 variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism comprising at least one of the variant polypeptide, the polynucleotide encoding the variant...
|
|
WO/2024/143438A1 |
The present invention addresses the problem of providing: a porous carrier which enables the acquisition of an extracellular vesicle by separating the extracellular vesicle with high purity in accordance with size and affinity; a method ...
|
|
WO/2024/144267A1 |
The present invention relates to a vaccine composition comprising an HIV-1 MRNA. The mRNA vaccine composition is prepared by deriving the common sequence of an HIV-1 antigen, and the immunogenicity of the vaccine composition is identifie...
|
|
WO/2024/144124A1 |
The present invention relates to: recombinant microorganisms having 2'-fucosyllactose production activity by having an exogenous enzyme related to GDP-L-fucose synthesis introduced thereinto and overexpressing the enzyme; a method for pr...
|
|
WO/2024/143154A1 |
Provided is a polypeptide that has an antibacterial activity and that includes: an amino acid sequence having a sequence identity of 85-100% with respect to an amino acid sequence of any one of SEQ ID NO. 1-6; or an amino acid sequence h...
|
|
WO/2024/138626A1 |
Disclosed are a helicase ToPif 1, and a preparation method therefor and a use thereof in high-throughput sequencing. The amino acid sequence of a ToPif 1 helicase mutant is as shown in SEQ ID NO. 1. The helicase can be used for controlli...
|
|
WO/2024/144614A1 |
The invention relates to the cDNA obtained from the RNA of Puccinellia distans, a plant species that naturally spreads in environments containing toxic amounts of boron, allowing excess boron to be excreted from the plant roots and has a...
|
|
WO/2024/145576A1 |
The presently disclosed subject matter provides immunoresponsive cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)), and expressing LIGHT. In certain embodiments, the engineered immunoresponsive ce...
|
|
WO/2024/143970A1 |
The present invention relates to a pepper plant simultaneously expressing a fluorescent protein and Cas9, and a preparation method therefor, and, more specifically, to a method for preparing a Cas9-overexpressing pepper transformant by u...
|
|
WO/2024/145638A2 |
The present invention provides new intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/140160A1 |
An expression of the human papilloma virus HPV39 L1 protein, virus-like particles, and a preparation method therefor. The preparation method comprises: truncating the amino acid sequence of the HPV39 L1 protein, carrying out codon optimi...
|
|
WO/2024/143439A1 |
The present invention addresses the problem of providing: a method for producing a recycled carrier via a cleaning method which can clean a carrier with high efficiency, and with little reduction of activity of a phosphatidylserine bindi...
|
|
WO/2024/138811A1 |
Provided in the present invention are a virion in the field of biology and the use thereof, and specifically provided are a plurality of adeno-associated virus mutants having a high muscle-targeting property, extremely low hepatotropism ...
|
|
WO/2024/145687A1 |
Provided herein are, inter alia, proteins comprising unnatural amino acids and arginine, pharmaceutical compositions comprising the proteins, and methods of enhancing the bioreactivity of proteins. In embodiments, the unnatural amino com...
|
|
WO/2024/138829A1 |
The present invention relates to a large-scale preparation method for compound nanoparticles. The compound nanoparticles are prepared from human serum albumin and polylactic acid by means of an emulsion-solvent evaporation method. The pr...
|
|
WO/2024/138472A1 |
Provided in the present invention are a porin monomer, a porin, a mutant thereof and the use of same. The porin monomer comprises: (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; or (b) a protein mutant the amino ac...
|
|
WO/2024/141788A1 |
The present disclosure relates to a genetically modified stem cells (e.g., mesenchymal stromal cells (MSCs) or pluripotent stem cells (PSCs)) and populations thereof, that comprise an exogenous nucleic acid that encodes a binding protein...
|
|
WO/2024/096545A9 |
The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using same.
|
|
WO/2024/144381A1 |
The present application relates to: a novel BBD29_RS02010 mutant polypeptide; a polynucleotide encoding the mutant polypeptide; a microorganism comprising one or more of the mutant polypeptide, the polynucleotide encoding the mutant poly...
|
|
WO/2024/138512A1 |
The present invention provides a novel porin BCP34, and a mutant thereof and a use thereof. Specifically, the wild-type porin BCP34 is a nonamer protein, and has a monomer of which the amino acid sequence is SEQ ID NO: 1; and the mutant ...
|
|
WO/2024/144515A1 |
The present invention relates to usage of cytokines, modulated by midkine, in accordance with the activities thereof in the treatment of autoimmune, viral, bacterial and fungal diseases, and in the elimination of the symptoms resulting f...
|
|
WO/2024/144272A1 |
The present invention relates to a vaccine composition comprising mRNA encoding the structural protein VP1 of a norovirus GI genotype. The mRNA vaccine composition was prepared by deriving the consensus sequence of a norovirus GI genotyp...
|
|
WO/2024/138382A1 |
Provided in the present invention are a porin monomer, a porin, a mutant thereof and the use thereof. The porin monomer comprises: (a) a protein composed of an amino acid sequence as shown in SEQ ID NO: 1; or (b) a protein mutant, wherei...
|
|
WO/2024/144372A1 |
The present invention relates to: a fusion protein comprising a peptide antigen and a human thioredoxin protein linked to the N-terminus, the C-terminus or both of the peptide antigen, wherein all cysteine residues in the amino acid sequ...
|
|
WO/2024/143785A1 |
The present invention relates to the manufacture of an elastin-like polypeptide-based recombinant protein and an animal cell expression platform thereof, particularly, an animal cell expression platform using a fusion recombinant protein...
|
|
WO/2024/145232A1 |
The present disclosure is directed to methods of purifying a dulaglutide composition. For example, the methods comprise loading the dulaglutide composition in-line with a buffer B solution onto a hydrophobic interaction chromatography (H...
|
|
WO/2024/142827A1 |
Provided is a production method which makes it possible to produce proteoglycan in a simpler manner compared with the conventional proteoglycan production methods and also makes it possible to perform the production of proteoglycan in wh...
|
|
WO/2024/143352A1 |
[Problem] To provide a peptide and use thereof. [Solution] Based on the results of original studies conducted to date, the present inventors designed an artificial sequence peptide having the amino acid sequence of SEQ ID NO: 1 and found...
|
|
WO/2024/145577A2 |
Described herein are peptide inhibitors of C. acnes hyaluronidase. Also described are method of using these peptide inhibitors to treat acne.
|
|
WO/2024/144057A1 |
The present application relates to: a novel tellurium-resistant membrane protein transporter polypeptide variant; a polynucleotide encoding the variant polypeptide; a microbe including the variant polypeptide, the polynucleotide encoding...
|
|
WO/2024/138424A1 |
Disclosed are a nanopore protein and an application thereof. The invention provides a pore protein which is (a), (b), or (c), below: a) a protein having an amino acid sequence such as that shown in SEQ ID NO: 1; b) a protein having 70% o...
|
|
WO/2024/141570A1 |
The invention relates to a composition comprising: - a first single-stranded nucleic acid molecule comprising a region complementary to a target and sites for recognition of a transposase; - a second single-stranded nucleic acid molecule...
|
|
WO/2024/145571A2 |
Provided herein are pre-protein signal peptides that direct secretion of expressed payload proteins from Lactobacillus bacteria. The pre-protein signal peptides described herein are designed for increased payload secretion over known sig...
|
|
WO/2024/140625A1 |
The present application relates to a mutable site in an NGF and a method for screening and/or identifying a mutable site, an NGF mutant library and a construction method therefor, an NGF mutant and a screening and/or identification metho...
|
|
WO/2024/141127A1 |
Disclosed are a peptide compound having an agonistic activity on a glucose-dependent insulinotropic polypeptide (GIP) receptor and the use thereof, which belong to the technical field of biological medicines. The compound has an increase...
|
